摘要
背景:脑脊液(CSF)中τ和淀粉样蛋白的测定已被广泛接受为一种辅助阿尔茨海默病(AD)临床诊断的诊断工具,而脑脊液则是一种辅助阿尔茨海默病(AD)临床诊断的工具。在大多数临床设置中没有常规获得。 因此,需要发现能够实现对AD特异性PRO的全面检测的更容易接近的外周生物标记物。血液和血液衍生物中的丁香。 目的:血小板含有神经元细胞中的蛋白质,包括τ蛋白。由于τ蛋白是AD神经病理学的特征之一,血小板τ蛋白可能与AD发病密切相关。D神经变性过程中发生的中枢神经过程。 方法:对25例AD患者和26例正常人血小板进行微管结合区、C端区和2个τ磷酸化位点(Ser 202/Thr 205和Thr 181)的分析。 结果:τ蛋白测定对AD患者和对照组无明显区别。但与MMSE>组相比,MMSE 24-27组C末端τ蛋白升高(p=0.049)。27例老年AD患者(>80岁)较年轻AD组(<80岁;p=0.009)和对照组(<80岁;p=0.011)有较高的t-τ蛋白表达。 结论:这些初步发现不仅证实了血小板tau蛋白可以被测量,而且表明血小板tau措施值得进一步研究,因为它们可能用于指示耳认知障碍的Ly分期。需要对更多的参与者进行进一步的研究,以证实我们的发现。
关键词: 老年痴呆症,血液,老年人,血小板,τ蛋白,神经病理学。
Current Alzheimer Research
Title:Platelet Tau Protein as a Potential Peripheral Biomarker in Alzheimer’s Disease: An Explorative Study
Volume: 15 Issue: 9
关键词: 老年痴呆症,血液,老年人,血小板,τ蛋白,神经病理学。
摘要: Background: Cerebrospinal fluid (CSF) measures of tau and amyloid proteins have now been largely accepted to be a diagnostic tool to aid the clinical diagnosis of Alzheimer's disease (AD), but CSF is not routinely obtained in most clinical settings. There is a need, therefore, to uncover additional readily accessible peripheral biomarkers that will enable comprehensive detection of AD-specific proteins in blood and blood derivates.
Objectives: Blood platelets contain proteins found in neuronal cell lines, including tau protein. Since tau protein is a characteristic of AD-neuropathology, platelet tau protein may be closely related to the central nervous process occurring in neurodegeneration.
Method: Platelets from 25 AD and 26 control subjects were analysed for the microtubule-binding and C-terminal region, as well as two tau phosphorylation sites (Ser202/Thr205 and Thr181).
Results: Tau protein measures did not discriminate between AD and control individuals. However, subjects with MMSE 24-27 had elevated C-terminal end tau protein (p=0.049) compared to those with MMSE >27, whereas older AD subjects (>80 years) showed higher t-tau protein in comparison to younger AD (<80 years; p=0.009) and control (<80 years; p=0.011) participants.
Conclusions: These initial findings not only confirm that platelet tau protein can be measured, but also indicate that platelet tau measures merit further study as they may be useful in indicating early stages of cognitive impairment. Further studies on larger number of participants are needed to confirm our findings.
Export Options
About this article
Cite this article as:
Platelet Tau Protein as a Potential Peripheral Biomarker in Alzheimer’s Disease: An Explorative Study, Current Alzheimer Research 2018; 15 (9) . https://dx.doi.org/10.2174/1567205015666180404165915
DOI https://dx.doi.org/10.2174/1567205015666180404165915 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ethanol Induced Oxidative Stress in the Vasculature: Friend or Foe
Current Hypertension Reviews Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Editorial (Thematic Issue: Special Issue for Current Pharmaceutical Biotechnology Miniaturized Platforms & Methods for Pharmaceutical Studies)
Current Pharmaceutical Biotechnology Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Mitochondrion as a Selective Target for the Treatment of Atherosclerosis: Role of Mitochondrial DNA Mutations and Defective Mitophagy in the Pathogenesis of Atherosclerosis and Chronic Inflammation
Current Neuropharmacology Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Protective Effects of Astragalus Membranaceus and Ligustrazine on Rat Brain Microvascular Endothelial Cell Injury after Oxygen-Glucose Deprivation/ Reoxygenation by Suppressing the PKCδ/MARCKS Pathway
Combinatorial Chemistry & High Throughput Screening Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development
Current Pharmaceutical Biotechnology Meet Our Co-Editor
Current Hypertension Reviews Immunotherapy and Targeted Therapy Combinations in Renal Cancer
Current Clinical Pharmacology Relationship Between Level of Heart Type Fatty Acid Binding Protein (Before and after Procedures) with Acute Renal Failure after PCI in Patients Under PCI
Cardiovascular & Hematological Disorders-Drug Targets The Protective Role of Crocus Sativus L. (Saffron) Against Ischemia- Reperfusion Injury, Hyperlipidemia and Atherosclerosis: Nature Opposing Cardiovascular Diseases
Current Cardiology Reviews There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses Analysis and Determination of Anti-diabetes Drug Acarbose and its Structural Analogs
Current Pharmaceutical Analysis